Cargando…
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Alzheimer's disease (AD) is the most common form of neurodegenerative dementia, affecting about 30 million people worldwide. Despite recent advances in understanding its molecular pathology, no mechanism-based drugs are currently available that can halt the progression of AD. Because amyloid-β-...
Autor principal: | Araki, Wataru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655040/ https://www.ncbi.nlm.nih.gov/pubmed/23531187 http://dx.doi.org/10.1186/1741-7015-11-82 |
Ejemplares similares
-
Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017) -
Oncology Drug Repurposing for Sepsis Treatment
por: Rumienczyk, Izabela, et al.
Publicado: (2022) -
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
por: Martinez, Miguel Angel
Publicado: (2021) -
Repurposing an HIV Drug for Zika Virus Therapy
por: Xie, Xuping, et al.
Publicado: (2019) -
Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Kiseleva, Anna A., et al.
Publicado: (2020)